Literature DB >> 21880279

Low-dose mifepristone increases uterine natural killer cell cytotoxicity and perforin expression during the receptive phase.

Feng Zhou1, Xiu-Ying Chen, Ya-Ling Zhuang, Yue-Zhou Chen, Li-Li Huang.   

Abstract

OBJECTIVE: To investigate the immunologic mechanism by which low-dose mifepristone serves as an anti-implantation contraceptive drug.
DESIGN: In vitro study.
SETTING: University hospital and research laboratory. PATIENT(S): Fifteen normally cycling patients at the "window of implantation." INTERVENTION(S): A human endometrial explant system was used to study the effects of low-dose mifepristone (65 and 200 nmol/L) on uterine natural killer (uNK) cells. Endometrial samples were treated with different concentrations of mifepristone. MAIN OUTCOME MEASURE(S): The cytotoxicity of uNK cells to K562 target cells and the expression of perforin (PFN) by uNK cells were examined using a methyl thiazolyl tetrazolium (MTT) assay and double immunohistochemistry, respectively. RESULT(S): Both uNK cell cytotoxicity and expression of PFN were increased after treatment with 65 or 200 nmol/L mifepristone, and these effects were dose-dependent. CONCLUSION(S): Mifepristone may negatively regulate implantation by increasing the cytotoxicity of uNK cells, and this increased cytotoxicity may result from increased PFN expression. These findings provide further evidence to support the potential contraceptive activity of low-dose mifepristone.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880279     DOI: 10.1016/j.fertnstert.2011.06.074

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Inflammation, leukocytes and menstruation.

Authors:  Jemma Evans; Lois A Salamonsen
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

Review 2.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

3.  Increased Uterine NK cell numbers and perforin expression during the implantation phase in IVF Cycles with GnRH Antagonist Protocol.

Authors:  Bufang Xu; Jingwen Wang; Lan Xia; Dan Zhang; Xian Wu; Aijun Zhang
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

4.  Progesterone Modulation of Pregnancy-Related Immune Responses.

Authors:  Nishel M Shah; Nesrina Imami; Mark R Johnson
Journal:  Front Immunol       Date:  2018-06-20       Impact factor: 7.561

5.  Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol.

Authors:  Jie Zhang; Yi-Fei Sun; Yue-Ming Xu; Bao-Jun Shi; Yan Han; Zhuo-Ye Luo; Zhi-Ming Zhao; Gui-Min Hao; Bu-Lang Gao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-17       Impact factor: 5.555

6.  Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis.

Authors:  Xiaoyan Qin; Wenjing Sun; Chong Wang; Mingjiang Li; Xingbo Zhao; Changzhong Li; Hui Zhang
Journal:  Reprod Biol Endocrinol       Date:  2021-07-21       Impact factor: 5.211

7.  Mifepristone increases the cytotoxicity of uterine natural killer cells by acting as a glucocorticoid antagonist via ERK activation.

Authors:  Yuezhou Chen; Yan Wang; Yaling Zhuang; Feng Zhou; Lili Huang
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

8.  Lack of in vitro effect of aglepristone on IFN-γ and IL-4 production by resting and mitogen-activated T cells of luteal bitches.

Authors:  Piotr Jurka; Lidia Szulc-Dąbrowska; Joanna Borkowska; Anna Winnicka
Journal:  BMC Vet Res       Date:  2013-10-26       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.